JP2023530456A5 - - Google Patents
Info
- Publication number
- JP2023530456A5 JP2023530456A5 JP2022577582A JP2022577582A JP2023530456A5 JP 2023530456 A5 JP2023530456 A5 JP 2023530456A5 JP 2022577582 A JP2022577582 A JP 2022577582A JP 2022577582 A JP2022577582 A JP 2022577582A JP 2023530456 A5 JP2023530456 A5 JP 2023530456A5
- Authority
- JP
- Japan
- Prior art keywords
- degrees
- crystal morphology
- peaks
- xrpd pattern
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040277P | 2020-06-17 | 2020-06-17 | |
| US63/040,277 | 2020-06-17 | ||
| PCT/US2021/037535 WO2021257643A1 (en) | 2020-06-17 | 2021-06-16 | Crystalline forms of a cd73 inhibitor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530456A JP2023530456A (ja) | 2023-07-18 |
| JP2023530456A5 true JP2023530456A5 (enExample) | 2024-06-24 |
Family
ID=76845331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022577582A Pending JP2023530456A (ja) | 2020-06-17 | 2021-06-16 | Ｃｄ７３阻害剤の結晶形態及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11649261B2 (enExample) |
| EP (1) | EP4168120A1 (enExample) |
| JP (1) | JP2023530456A (enExample) |
| KR (1) | KR20230026312A (enExample) |
| CN (1) | CN115942977A (enExample) |
| AU (1) | AU2021292195A1 (enExample) |
| CA (1) | CA3179320A1 (enExample) |
| WO (1) | WO2021257643A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201805506YA (en) | 2016-01-08 | 2018-07-30 | Arcus Biosciences Inc | Modulators of 5'-nucleotidase, ecto and the use thereof |
| EP3893891A4 (en) | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
| WO2020185859A1 (en) * | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| AU2021292195A1 (en) * | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| KR20250004779A (ko) | 2022-04-13 | 2025-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Trop-2 발현 암을 치료하기 위한 병용 요법 |
| CN120091809A (zh) | 2022-10-20 | 2025-06-03 | 艾库斯生物科学有限公司 | Cd73化合物的冻干制剂 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| EP2949670B1 (en) | 2009-12-10 | 2019-02-27 | F. Hoffmann-La Roche AG | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| KR101656548B1 (ko) | 2010-03-05 | 2016-09-09 | 에프. 호프만-라 로슈 아게 | 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도 |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| SMT201900074T1 (it) | 2010-05-04 | 2019-02-28 | Five Prime Therapeutics Inc | Anticorpi che legano csf1r |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| CN104093740B (zh) | 2012-02-06 | 2018-01-09 | 弗·哈夫曼-拉罗切有限公司 | 使用csf1r抑制剂的组合物和方法 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| CN104684582A (zh) | 2012-08-31 | 2015-06-03 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| US9090697B2 (en) | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| EP3134411B1 (en) | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| SG11201805506YA (en) | 2016-01-08 | 2018-07-30 | Arcus Biosciences Inc | Modulators of 5'-nucleotidase, ecto and the use thereof |
| TWI781136B (zh) | 2017-01-20 | 2022-10-21 | 美商阿克思生物科學有限公司 | 用於治療癌症相關病症之唑嘧啶 |
| WO2018204661A1 (en) | 2017-05-05 | 2018-11-08 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| WO2018213377A1 (en) | 2017-05-17 | 2018-11-22 | Arcus Biosciences, Inc. | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
| AU2019231781B2 (en) * | 2018-03-09 | 2025-02-13 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| WO2020023846A1 (en) | 2018-07-27 | 2020-01-30 | Arcus Biosciences, Inc. | Pyridone a2r antagonists |
| WO2020102646A2 (en) | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| EP3893891A4 (en) | 2018-12-13 | 2022-08-03 | Arcus Biosciences, Inc. | SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT |
| US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
| AU2021292195A1 (en) * | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
-
2021
- 2021-06-16 AU AU2021292195A patent/AU2021292195A1/en active Pending
- 2021-06-16 US US17/348,833 patent/US11649261B2/en active Active
- 2021-06-16 EP EP21739852.8A patent/EP4168120A1/en active Pending
- 2021-06-16 WO PCT/US2021/037535 patent/WO2021257643A1/en not_active Ceased
- 2021-06-16 CN CN202180042946.2A patent/CN115942977A/zh active Pending
- 2021-06-16 KR KR1020227042950A patent/KR20230026312A/ko active Pending
- 2021-06-16 JP JP2022577582A patent/JP2023530456A/ja active Pending
- 2021-06-16 CA CA3179320A patent/CA3179320A1/en active Pending
-
2023
- 2023-04-07 US US18/297,398 patent/US12281136B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2750413C (en) | Hydroxamic acid derivatives | |
| JP2020111618A5 (enExample) | ||
| JP2022515273A (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JP2016503414A5 (enExample) | ||
| JP2015512942A5 (enExample) | ||
| JP2021513965A5 (enExample) | ||
| JP2021515775A5 (enExample) | ||
| JP3200421B2 (ja) | 化学療法剤としての新規ビス白金錯体 | |
| JP2024519188A5 (enExample) | ||
| JP2021531273A5 (enExample) | ||
| TWI829329B (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| CN103848815B (zh) | 含脲基片段的4-取代-6-苯基嘧啶衍生物及其制备方法和用途 | |
| CN104327050A (zh) | 一种吖啶酰胺基硫脲类衍生物及其制备方法和用途 | |
| Ge et al. | Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of trithe ple-negative breast cancer | |
| US10111955B2 (en) | PEG derivative | |
| Fouladdel et al. | Synthesis and cytotoxicity of some biurets against human breast cancer T47D cell line | |
| JP7861083B2 (ja) | Ｆａｋ阻害剤およびその併用薬物 | |
| CN104072624B (zh) | 一种多胺改性高分子药物及其制备方法与作为抗肿瘤药物的应用 | |
| CN102503908B (zh) | 维a酸衍生物、其制备方法、其药物组合物及其在制备抗肿瘤药物中的应用 | |
| CN112585149B (zh) | 膦过渡金属配位化合物、其制造方法和抗癌剂 | |
| CA2456550A1 (en) | Tumour inhibiting cerium compounds | |
| JP5161434B2 (ja) | 抗癌剤 | |
| JP2026515180A (ja) | ３－（５，７－ジフルオロ－４－オキソ－１，４－ジヒドロキノリン－２－イル）－４－（メチルスルホニル）ベンゾニトリルの結晶形態 |